JP2004516236A5 - - Google Patents

Download PDF

Info

Publication number
JP2004516236A5
JP2004516236A5 JP2001583806A JP2001583806A JP2004516236A5 JP 2004516236 A5 JP2004516236 A5 JP 2004516236A5 JP 2001583806 A JP2001583806 A JP 2001583806A JP 2001583806 A JP2001583806 A JP 2001583806A JP 2004516236 A5 JP2004516236 A5 JP 2004516236A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
antibody
composition according
factor
antibody fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001583806A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004516236A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2000/027438 external-priority patent/WO2001087339A1/en
Publication of JP2004516236A publication Critical patent/JP2004516236A/ja
Publication of JP2004516236A5 publication Critical patent/JP2004516236A5/ja
Pending legal-status Critical Current

Links

JP2001583806A 2000-05-15 2000-10-05 抗血栓剤 Pending JP2004516236A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57143400A 2000-05-15 2000-05-15
PCT/US2000/027438 WO2001087339A1 (en) 2000-05-15 2000-10-05 Antithrombotic agents

Publications (2)

Publication Number Publication Date
JP2004516236A JP2004516236A (ja) 2004-06-03
JP2004516236A5 true JP2004516236A5 (enExample) 2007-11-22

Family

ID=24283688

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001583806A Pending JP2004516236A (ja) 2000-05-15 2000-10-05 抗血栓剤

Country Status (20)

Country Link
US (1) US20050037006A1 (enExample)
EP (2) EP1825864A3 (enExample)
JP (1) JP2004516236A (enExample)
KR (2) KR20070116192A (enExample)
CN (2) CN100339132C (enExample)
AT (1) ATE345816T1 (enExample)
AU (2) AU2000278584B2 (enExample)
BR (1) BR0015872A (enExample)
CA (1) CA2411369A1 (enExample)
CZ (1) CZ20023778A3 (enExample)
DE (1) DE60032029T2 (enExample)
ES (1) ES2277597T3 (enExample)
HU (1) HU225874B1 (enExample)
IL (1) IL152831A0 (enExample)
MX (1) MXPA02011385A (enExample)
NO (1) NO20025463L (enExample)
NZ (1) NZ522632A (enExample)
PL (1) PL360060A1 (enExample)
WO (1) WO2001087339A1 (enExample)
ZA (1) ZA200209265B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2438913T3 (da) 2002-03-20 2020-06-22 Univ Maryland Ikke-selektiv kationkanal i neurale celler og forbindelser, der blokerer kanalen, til anvendelse i behandling af opsvulmning af hjernen
US8980952B2 (en) 2002-03-20 2015-03-17 University Of Maryland, Baltimore Methods for treating brain swelling with a compound that blocks a non-selective cation channel
ATE486606T1 (de) 2004-09-18 2010-11-15 Univ Maryland Therapeutische mittel zum targeting des ncca-atp- kanals und verwendungsverfahren dafür
AU2005287090A1 (en) 2004-09-18 2006-03-30 Department Of Veterans Affairs Therapeutic agents targeting the NCca-ATP channel and methods of use thereof
WO2008089103A2 (en) 2007-01-12 2008-07-24 University Of Maryland, Baltimore Targeting ncca-atp channel for organ protection following ischemic episode
CA3065983C (en) 2007-06-22 2022-07-26 The United States Of America As Represented By The Department Of Veterans Affairs Inhibitors of ncca-atp channels for therapy
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
ES2566963T3 (es) * 2007-11-21 2016-04-18 Oregon Health & Science University Anticuerpos monoclonales anti-factor XI y métodos de uso de los mismos
US9518128B2 (en) 2011-12-14 2016-12-13 Janssen Pharmaceuticals, Inc. Thrombin-binding antibody molecules
GB201121513D0 (en) * 2011-12-14 2012-01-25 Cambridge Entpr Ltd Thrombin-binding antibody molecules and uses thereof
US20200231701A1 (en) * 2016-12-23 2020-07-23 Novartis Ag Methods of treatment with anti-factor xi/xia antibodies
US20240018503A1 (en) * 2017-04-27 2024-01-18 Chugai Seiyaku Kabushiki Kaisha Coagulation factor ix with improved pharmacokinetics
EP3617316A4 (en) 2017-04-27 2020-12-23 Chugai Seiyaku Kabushiki Kaisha COAGULATION FACTOR IX WITH IMPROVED PHARMACOKINETICS
CN115448985A (zh) * 2021-06-08 2022-12-09 上海循曜生物科技有限公司 新型抗栓抗体

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2049655C (en) * 1990-09-17 1996-11-12 Akio Odawara Pharmaceutical composition for inhibiting platelet aggregation
MA24512A1 (fr) * 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
WO2000007626A1 (en) * 1998-08-07 2000-02-17 Smithkline Beecham Corporation Use of anti-coagulation factor antibodies as long-lasting protective agents
DE69901569T2 (de) * 1998-08-28 2002-12-19 Genentech, Inc. Humane antikörper gegen faktor ix/ixa

Similar Documents

Publication Publication Date Title
LU92255I2 (fr) Ocriplasmine et ses dérivés pharmaceutiquement acceptables (JETREA)
Lijnen et al. Fibrinolytic agents: mechanisms of activity and pharmacology
DE60143393D1 (de) Modifizierte formen pharmazeutisch aktiver agenzien und verwendungen dafür
WO2002095007A3 (en) Conjugates activated by cell surface proteases and therapeutic uses thereof
MXPA04005755A (es) Combinacion de inhibidores de proteasa dependientes del citocromo p450.
WO2001070204A3 (de) Hochselektive inhibitoren des urokinase-plasminogenaktivators
WO2001068645A3 (en) N-cyanomethylcarboxamides and their use as protease inhibitors
EP1825864A3 (en) Antithrombotic agents
WO2003008637A3 (en) Use of genotyping in the individualization of therapy
PT1227797E (pt) Formulacoes farmaceuticas de dispersao solida
WO2002057246A3 (en) Inhibitors of cruzipain and other cysteine proteases
SE0000303D0 (sv) Novel compounds
WO2003053999A3 (de) Selektive arylguanidinpeptide als urokinaseinhibitoren
CA2007075A1 (en) New thrombolytic compositions
BRPI0317780B8 (pt) uso de supositório de estreptoquinase com ação trombolítica
AU2712799A (en) The use of estradiol derivatives for treating side-effects during and/or after gnrha therapy
Thomson New thrombolytic drugs
MY120631A (en) Novel pharmaceutical combination having analgesic activity
JP2001521898A5 (ja) 心筋虚血およびアンギナの処置用医薬の製造のためのキナプリルの使用